Acute myeloid leukemia (AML) is a hetero geneous malignant disorder originating from mutations in progenitor cells that lead to the unrestrained proliferation of undifferentiated myeloblasts (Löwenberg et al., 1999) . There is a general consensus that the molecular events leading to AML leukemogenesis occur as a multistep process (Kelly and Gilliland, 2002; Gilliland et al., 2004) . Those events are broadly classified into two groups: gene alterations that confer a proliferative and/or survival advan tage to hematopoietic progenitors (e.g., RAS, Differentiating agents have been proposed to overcome the impaired cellular differentiation in acute myeloid leukemia (AML). However, only the combinations of all-trans retinoic acid or arsenic trioxide with chemotherapy have been successful, and only in treating acute promyelocytic leukemia (also called AML3). We show that iron homeostasis is an effective target in the treatment of AML. Iron chelating therapy induces the differentiation of leukemia blasts and normal bone marrow precursors into monocytes/macrophages in a manner involving modulation of reactive oxygen species expression and the activation of mitogen-activated protein kinases (MAPKs). 30% of the genes most strongly induced by iron deprivation are also targeted by vitamin D3 (VD), a well known differentiating agent. Iron chelating agents induce expression and phosphorylation of the VD receptor (VDR), and iron deprivation and VD act synergistically. VD magnifies activation of MAPK JNK and the induction of VDR target genes. When used to treat one AML patient refractory to chemotherapy, the combination of iron-chelating agents and VD resulted in reversal of pancytopenia and in blast differentiation. We propose that iron availability modulates myeloid cell commitment and that targeting this cellular differentiation pathway together with conventional differentiating agents provides new therapeutic modalities for AML. Like ATRA, VD belongs to the steroid superfamily and plays a critical role in regulating numerous cellular and physi ological responses. VD associates with its cognate receptor (VDR) to form a heterodimer with the retinoid X receptor. This complex then binds to the VD responsive element, which is present in the promoter region of target genes, thereby inducing changes in gene transcription (Hughes et al., 2009 ). VD also activates a variety of protein kinases, such as the three families of mitogenactivated protein kinase (MAPK; ERK, JNK, and p38), protein kinase C, or Src fam ily kinases by alternative signaling pathways which are not fully characterized (Wang et al., 2003) . The active metabolite of VD, 1,25(OH) 2 D 3 , which is known as calcitriol, has anti proliferative effects, can activate apoptotic pathways, and can inhibit angiogenesis (Deeb et al., 2007) . In the hemato poietic system, numerous studies on AML blasts, leukemic cell lines, and primary myeloid precursors showed that VD induces cell differentiation into monocytes (Abe et al., 1981; Koeffler et al., 1984; Hmama et al., 1999; Bastie et al., 2004; Ji and Studzinski, 2004; Gemelli et al., 2008; Hughes et al., 2009) . Encouraging clinical trials have suggested that VD could be effective as a differentiating agent in the treatment of AML and myelodysplastic syndrome (MDS), but hypercal cemia has limited its use (Ferrero et al., 2004; Srivastava and Ambrus, 2004; Deeb et al., 2007) .
Iron (Fe) is required as a cofactor for several critical cellu lar enzymes involved in energy metabolism and cell prolifera tion and is therefore essential for all living cells. Iron exists in two oxidation states, the ferrous (Fe 2+ ) and the ferric (Fe 3+ ) forms, which participate to the generation of reactive oxygen species (ROS) through the Fenton reaction. In this process, free cytosolic iron generates hydroxide anions and hydroxyl radicals from hydrogen peroxide (Fe 2+ + H 2 0 2 ↔Fe 3+ + OH  + OH • ; Fenton et al., 1964) which can lead to cellular damages (Davies, 2005) . Therefore, iron chelators have been proposed to be antioxidant agents (Kalyanaraman, 2007) . However, iron chelators have also been shown to induce the generation of ROS under specific conditions (Chaston et al., 2004) .
The transferrin receptor (CD71/TfR1) is an evolution arily conserved receptor that is essential for the uptake of iron in mammalian cells (Trowbridge and Shackelford, 1986; FLT3, or KIT mutations) and gene alterations/point mu tations in transcription factors or transcriptional coactivators (e.g., CEBP and NPM1) that affect differentiation (Fröhling et al., 2005; Roumier et al., 2006; Renneville et al., 2008) . The most important transcription factors that have been impli cated in the myelomonocytic development are PU1 for early myeloid commitment, C/EBP for granulocyte maturation, and vitamin D3 (VD) receptor (VDR) and MafB for monocyte macrophage differentiation (Sieweke and Graf, 1998; Friedman, 2002; Mueller et al., 2002; Gemelli et al., 2008) .
The potential of the currently available cytotoxic chemo therapies to treat AML might have reached its limit (Löwenberg et al., 1999; Ravandi et al., 2007) . Moreover, the majority of patients with AML are 60 yr of age or older and, in this population, highdose chemotherapy is associated with a high rate of morbidity and mortality. Although results of new therapeutic strategies have improved steadily in younger adults over the last 20 yr, there have been fewer improve ments in outcome among elderly patients (Löwenberg et al., 2009) . Based on the emerging knowledge of the biology of AML, new targeted therapeutic approaches need to be devel oped to interrupt proliferation, induce apoptosis, and/or override the differentiation block.
The current treatment modality for the induction of a terminal differentiation program in AML has only been achieved in acute promyelocytic leukemia (APL or AML3) by the use of differentiating agents combined with chemo therapy (Chen et al., 1994; Zhu et al., 2001; Wang and Chen, 2008) . In most of the cases, APLs are characterized by the translocation t(15;17), which encodes a fusion of the promy elocytic leukemia and retinoic acid receptor  proteins. The use of alltrans retinoic acid (ATRA) with chemotherapy was a major breakthrough in APL therapy. It has dramatically improved the prognosis from poor to a high cure rate (90% of patients; Wang and Chen, 2008) . The use of arsenic triox ide (ATO) since the early 1990s further improved the clinical outcome of refractory or relapsed as well as newly diagnosed APL (Wang and Chen, 2008) . Current evidences are now available to show that differentiation is not the only mecha nism explaining the therapeutic efficacy of ATRA or ATO in clearing APL, as retinoic acid also triggers growth arrest of leukemia initiating cells (Nasr et al., 2008) . different iron deprivation treatments, in contrast to many genes (1,094) that are altered by the iron chelators DFO and DFX. Genes with an intensity >50 and a p-value <0.001 were considered relevant. (b) Fold change variations of gene expression in differentiated cells relative to untreated cells. A24 and the iron chelators up-regulated monocyte/macrophage-specific genes and down-regulated myelocyte-specific genes. Up-regulation is represented on the positive scale, and down-regulation is indicated on the negative scale. (c) Fold increase of CD14 and CD11b expression after flow cytometry (mean fluorescence intensity [MFI] relative to untreated cells) in HL60 cell line treated with 10 µg/ml A24, 5 µM DFO, or 3 µM DFX for 72 h (mean ± SEM, n = 3). (d) Fold increase of CD14 and CD11b expression evaluated by flow cytometry (MFI relative to untreated cells) in U937 (white), THP1 (dark gray), OCI-AML3 (black), and NB4 (light gray) cell lines treated with 10 µg/ml A24, 5 µM DFO, or 3 µM DFX for 72 h (mean ± SEM, n = 3). (e) MGG-stained cytospins of HL60 cells treated with 250 nM VD, 10 µg/ml A24, 5 µM DFO, or 3 µM DFX for 72 h. The control cells show an immature myeloblastic phenotype: a high nucleusto-cytoplasm ratio, a hyperbasophilic cytoplasm, and numerous azurophilic granules. The A24-or iron chelator-treated cells show a decrease in the nucleus-to-cytoplasm ratio, the loss of granules, and cytoplasmic basophilia and irregular cytoplasmic contours, all typical of mature monocytes. Bars, 10 µm. Representative photos of three independent experiments are shown. (f) FACS analysis of CD14 expression in HL60 cells treated with A24 (green line), DFO, and DFX (blue lines) in the presence or absence of 5 µM FeCl 3 (gray line) for 72 h. The filled histograms represent staining with the isotype control antibody. One representative experiment of three experiments is shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Lim et al., 1987; Daniels et al., 2006b) . Cancer cells over express TfR1 and are more sensitive to iron depletion than their normal counterparts, most probably because of their high proliferative capacities (Faulk et al., 1980; Gatter et al., 1983) . TfR1 is a validated target for anticancer therapy using both mAbs and drugconjugated transferrin (Trowbridge and Domingo, 1981; Daniels et al., 2006a) . We have previously characterized an antiTfR1 antibody (A24) that exhibits potential activity as a therapeutic anticancer agent (Moura et al., 2001) . A24 specifically binds to TfR1 high cells, competes with ironloaded transferrin (FeTf) for receptor binding, and impairs receptor recycling, thereby drastically impairing iron uptake (Moura et al., 2004; Lepelletier et al., 2007; Callens et al., 2008) . Iron chelators have also been pro posed for several years as an alternative anticancer therapy and effectively induce cell growth arrest and apoptosis in cancer cells in vitro and in vivo (Richardson et al., 1994 (Richardson et al., , 2009 Le and Richardson, 2004; Whitnall et al., 2006) . , DFX (0-10 µM), or VP16 (0-100 ng/ml) for 72 h, followed by a 16-h period of [ 3 H]-thymidine incorporation. Thymidine incorporation (percentage over the control) was plotted as the mean ± SEM of grouped M0/M1/M2 (n = 6) or M4/M5 (n = 9) subtypes patients. Cell proliferation for each patient was measured in triplicate. (b) HL60 cells were cultured in the presence or absence of 10 µg/ml A24 or 5 µM DFO for 72 h. Early and late apoptosis was evaluated by flow cytometry using annexin V-FITC/PI labeling (mean ± SEM, n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001. (c) CD14 and CD11b expression in blasts from AML patients treated with A24 and DFO for 72 h. The expression of the differentiation markers was normalized by calculating the fold increase of the MFI relative to the control cells. The filled symbols represent the M0/M1/M2 AML subtypes, and the M4/M5 subtypes are empty symbols. One representative experiment of three is presented for each patient. The mean (horizontal bars) of the eight patients is shown.
Induction of cell surface markers in treated cells was accompanied by the characteristic cytological modifications of monocytes, i.e., cytoplasm enlargement and loss of both cytoplasmic basophilia and azurophilic granules ( Fig. 1 e and  Fig. S1 c) . Moreover, HL60 differentiated cells acquired functional properties of monocytes such as esterase activity (Fig. S1 d) .
Supplementation of cultures with an excess of soluble iron abrogated expression of differentiation markers induced by iron deprivation (Fig. 1 f) but not by ATRA and VD (Fig. S2) , confirming the role of iron availability in AML cell differ entiation. We next investigated whether primary cells from AML patients could also be sensitive to iron deprivation therapy. Fresh AML blasts from different AML subtypes (categorized according to the FrenchAmericanBritish [FAB] classification system [Bennett et al., 1976] ) were iso lated at the time of diagnosis (Table S2 , complete list of AML subtypes and biological parameters for the patients used in this study) and were cultured in the presence of A24 and DFO. An arrest of cell proliferation (Fig. 2 a) and induction of apoptosis (Fig. 2 b) were observed concomi tantly to CD14 and CD11b expression (Fig. 2 c) , indicating that, similar to cell lines, blasts from different AML sub types, even if heterogeneous in the oncogenic events lead ing to their arrest in differentiation (Löwenberg et al., 1999) , are susceptible to differentiation therapy based on iron deprivation.
Targeting of iron homeostasis induces primary progenitor differentiation toward the monocyte lineage
To verify if iron homeostasis plays a role in the differentia tion of primary granulocytes and monocytes, we tested the effect of iron deprivation on hematopoietic cord blood pro genitors. Iron deprivation agents did not change the total number of colonies derived from CD34 + cells in methylcel lulose plates (unpublished data). However, treatment with the iron chelators resulted in an increased number of bipo tent CFUGM colonies (Fig. 3 a) and enhanced the ratio of CFUM to the detriment of CFUG colonies (Fig. 3 b) , suggesting that chelating iron from hematopoietic precur sors induces commitment toward the monocyte over the granulocyte lineage. As expected, because iron is necessary for hemoglobin synthesis (Adamson, 1994 ) the number of CFUE colonies was reduced by all the iron deprivation agents (Fig. 3 c) .
When differentiation of CD34 + cord blood progenitors into granulocytes was induced in liquid cultures (Fig. S3) , >65% of cells were polymorphonuclear cells after 18 d. We therefore added A24 or iron chelators to these granu locyteoriented cell cultures every 3 d, at concentrations which did not induce cell toxicity (unpublished data). Under these conditions, iron deprivation did not affect cord blood cell proliferation (Fig. 3 d) but rather enhanced their commitment toward the monocyte lineage because there was a consistent upregulation of genes coding for tran scription factors specific for the monocyte lineage, such as The molecular mechanisms underlying the antitumor effect of ironchelating therapeutic approaches still need to be fully elucidated (Napier et al., 2005; Fu and Richardson, 2007) . We aimed to characterize these mechanisms and to validate their potential value in AML therapy. In this paper, we show in vivo, in vitro, and ex vivo that targeting iron homeostasis induces blast differentiation toward the mono cyte lineage, which is dependent on the modulation of ROS levels and the activation of the MAPK pathway. Importantly, iron deprivation induces VDR gene expression and VDR phosphorylation, providing the rationale for the combination of iron chelation and VD therapies. The synergistic effect of this association amplified the activation of the MAPK-JNK pathway and VDRtargeted genes. Finally, we provide data, in the form of a case report, showing the efficacy of this combina tion in the induction of tumor cell differentiation in an AML patient. This study provides the proof of concept for the use of combination of iron chelators and VD in AML therapy.
RESULTS

Targeting of iron homeostasis induces AML cell differentiation
To gain new insights in the molecular mechanisms in volved in the antitumor activity of ironchelating therapeu tic approaches, we sought to identify genes that are affected both by iron chelators (deferoxamine [DFO] and deferasirox [DFX] ) and by impairment of FeTf uptake (using the anti TfR1 mAb A24 [Moura et al., 2004; Lepelletier et al., 2007; Callens et al., 2008] ). Indeed, A24 targets TfR1 (the major receptor involved in the iron entry in the cells), whereas iron chelators can also capture other bivalent ions (e.g. Mn 2+ , Cu 2+ , or Zn 2+ ) which could modulate genes irrelevant to iron homeostasis. Thus, identification of overlapping genes allows us to avoid selecting offtarget genes. We focused our first studies in a cell line (HL60) to avoid heterogeneity in the data related to the multiple genetic events that have been implicated in AML oncogenesis. An analysis of the collected data revealed that 105 genes were similarly modulated by the three iron deprivation agents ( Fig. 1 a and Table S1 ). Among these genes, several were related to cell differentiation. Markers of monocytes or activated macrophages were upregulated, whereas granulocyte markers were downregulated ( Fig. 1 b) . These results were confirmed by realtime quantitative PCR and extended to other AML cell lines from different AML subtypes (Fig. S1 a) .
We further tested the ability of iron deprivation to override the block of cell differentiation observed in AML cells. We followed the expression of CD14 and CD11b monocyte cell surface markers (Kansas et al., 1990 ) after iron deprivation induced by treatment with A24, DFO, or DFX. Expression of both markers was induced by iron deprivation, suggesting that cells underwent differentiation ( Fig. 1 c) similar to VD treated cells (Fig. S1 b) . Upregulation of monocyte cell sur face markers, initially detected in myeloblastic cells (HL60), was also observed in cell lines from myelo/monoblastic (OCI AML3), monoblastic (U937 and THP1), and pro myelocytic (NB4) origin (Fig. 1 d) . Polymorphonuclear neutrophils are present in the majority of the control cultures, whereas monocytes and macrophages are predominantly present under iron deprivation conditions. The histograms represent the percentage of each leukocyte population from MGG-colored cytospins at day 18 (mean ± SEM, three independent counts of 100 cells each). Bars, 10 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (Sieweke et al., 1996; Kelly and Gilliland, 2002; Taghon et al., 2002; Friedman, 2007; Fig. 3 e) . Cytological examination confirmed that the mono cyte cell number was higher in ironpoor cultures (Fig. 3 f) .
HOXA10, EGR1, and MafB
Therefore, in hematopoiesis, iron availability could be an important factor in determining whether a hematopoi etic progenitor cell differentiates toward a monocyte or a granulocyte. al., 2009) . By comparing the pattern of genes induced by VD and by ironchelating agents in a nonsupervised tran scriptome analysis, we found a high similarity between the differentially expressed genes; of the 105 genes that were modulated by iron deprivation, 30 were also modulated by treatment with VD ( Fig. 6 a and Table S3 ). Both VD and the ironchelating agents upregulated monocyte markers and downregulated neutrophil markers (Fig. 6 b) . Moreover, in gene chips (Fig. 6 c) and realtime quantitative PCR (Fig. 6 d) analysis, transcription of the c-Jun gene was induced by both VD and iron deprivation. Transcripts coding for c-Fos were also upregulated by both treatments (Fig. 6 d) , suggesting the involvement of the JNK pathway. Similar results were observed in cell lines from different AML subtypes (Fig. 6 e) . To further address the role of JNK, cells were transfected with micro RNA (miRNA) constructs specific for different members of the JNK pathway (namely JNK1, JNK2, and cJun; Fig. S5 , a-c). miRNA-mediated silencing of cJun, JNK1, and JNK2 markedly abrogated cell differentiation induced by iron deprivation agents (Fig. 6 f) . Overexpression of each one of the two JNK proteins revealed that JNK1 was the most effective to induce cell differentiation of AML cells (Fig. 6 g) .
Given the high similarities shared between VD and iron deprivation agents to induce cell differentiation, we investi gated whether iron deprivation of cells could induce VDR signaling (Wang et al., 2003; Himes et al., 2006) . As ob served for its cognate ligand VD, VDR expression was in duced in cells treated by ironchelating agents (Fig. 6 h) . The addition of iron chelators to cells starved of growth factors readily induced the VDR phosphorylation (Fig. 6 i) involved in the control of VDR activity (Jurutka et al., 1996) . Altogether, these results indicate that ironchelating agents are able to induce cell differentiation through the activation of JNK pathway. Iron deprivation also potenti ates VDR signaling pathway through VDR expression and VDR phosphorylation.
VD synergizes with iron deprivation agents through the activation of the Jun pathway to induce cellular differentiation Treatment of cells with both iron chelators and VD drasti cally increased the upregulation of monocyte markers CD11b and CD14 (Fig. 7 a) . We consequently investigated whether the combination of ironchelating agents (as the iron chelator DFO and the antiTfR1 A24) and VD had a synergistic effect. Applying the combination index (CI) iso bologram method (Chou and Talalay, 1984) , we evaluated interactions between DFO and VD, or A24 and VD (Figs. S6, . At the concentration inducing 50% of CD14 + cells, CI values for the combination of DFO and VD, or A24 and VD, were <1 (0.87 and 0.89, respectively), indicating a syn ergistic interaction. Both combinations were accompanied by morphological changes in the treated cells (Fig. 7 b) and by higher expression of VDR (Fig. 7 c) . The physiological relevance of increased VDR gene expression was demon strated by the robust increase in the transcription of its Iron deprivation-induced cell differentiation is dependent on the modulation of ROS levels ROS production is highly dependent on the intracellular labile iron pool (LIP). Therefore, to investigate whether ironchelating agents modulate ROS levels in AML cells, we used a metallosensor fluorescent probe (calcein) for LIP measurements (Espósito et al., 2002) and dihydrorhodamine 123 (DHR123) as an indicator of the degree of general oxi dative stress or dihydroethidium (DHE) to monitor cellular superoxide production (OwusuAnsah et al., 2008) . As expected, previous addition of iron deprivation agents de creased LIP levels in AML cells and DFX was the fastest and most efficient compound (Fig. S4, a-c) . Iron deprivation of cells by DFX (the most permeant chelators) was readily ac companied by ROS formation (Fig. 4 a) , which was found to be concentration (Fig. 4 b) and time (Fig. 4 c) dependent. We further confirmed the specificity of ROS detection by preincubating irondeprived cells with the antioxidant Nacetyllcysteine (NAC; Fig. 4 d) .
Iron chelators had opposite effects depending on whether AML cells were treated during short (1-3 h; Fig. 4 , a-d) or long (16-18 h; Fig. S4 , d-f) periods of time. In addition, in HL60cultured cells treated for 16-18 h with iron chelators, the H 2 O 2 mediated generation of ROS was abrogated in a dosedependent manner (Fig. S4, d and e), whereas ATO in duced a sustained production of ROS in NB4 cells (Fig. S4 f) .
To further clarify which of the pro or antioxidant ef fects of iron chelators was implicated in monocyte differenti ation, irondeprived AML cells were treated with or without the antioxidants NAC or pyrrolidine dithiocarbamate (PDTC). Antioxidant prevented the increase in CD14 mediated by iron deprivation differentiation, suggesting that cell differen tiation is dependent on the increased ROS levels induced during the early course of cellular iron deprivation (Fig. 4 , e and f). Thus, irondepriving agents control cell differen tiation through modulation of ROS levels.
Cell differentiation induced by iron deprivation is dependent on the activation of the MAPK pathway
MAPKs are serine/threonine protein kinases crucial to sev eral biological responses including stress responses to ROS (Whitmarsh and Davis, 1999) . The addition of the specific inhibitors of ERK, JNK, and p38 MAPK signaling pathways (which characterize the three MAPK families) abrogated cell differentiation induced by iron deprivation agents (Fig. 5 a) . The ironchelating agents induced the phosphorylation of ERK, p38, and JNK (Fig. 5 b) . However, only inhibitors of JNK and p38, but not of ERK, prevented iron deprivationinduced apoptosis (Fig. 5 c) .
Iron deprivation-induced cell differentiation shares high similarity with that induced by VD VD can induce monocyte/macrophage differentiation of both primary cells and myeloid leukemia cell lines (Abe et al., 1981; Koeffler et al., 1984; Hmama et al., 1999; Bastie et al., 2004; Ji and Studzinski, 2004; Gemelli et al., 2008 ; Hughes iron chelators was specific to VDR signaling because iron chelators did not potentiate the ability of ATRA to promote cell differentiation in HL60 cells (Fig. S7) . Finally, the effi cacy of the combined therapy was validated ex vivo in pri mary cells from AML patients (Fig. 7 g ).
downstream target genes, cathelicidin (1,000fold increase) and CYP24A (6,000fold increase; Fig. 7 d) , and c-Fos and c-Jun (Fig. 7 e) . Moreover, the phosphorylation of JNK increased in response to treatment with both VD and iron deprivation (Fig. 7 f) . The combined effect of VD and CD14 expression was evaluated 72 h after treatments (mean ± SEM, n = 3). (h) VDR mRNA level evaluated by quantitative RT-PCR and normalized to GAPDH mRNA in HL60 cells treated for 48 h with the indicated agents (A24, 10 µg/ml or DFO, 5 µM; mean ± SEM, n = 4). *, P < 0.05; **, P < 0.01; ***, P < 0.001. (i) Serum-starved HL60 and U937 cells were incubated with 0.5 µM H 2 O 2 , 10 µg/ml A24, or 3 µM DFO for 10 min at 37°C. Phosphorylation of VDR (P-VDR) in whole cell extracts was analyzed by immunoblotting. VDR was used as loading control. One representative experiment of three is shown.
In vivo efficacy of combined iron homeostasis and VD treatment through the activation of the MAPK-JNK pathway
Based on these observations, we postulated that the combina tion of iron deprivation and VD could intensify their anti leukemic properties. Therefore, the efficacy of differentiation therapy was further evaluated in vivo in a mouse tumor xe nograft model. A single dose of A24 completely inhibited the growth of HL60 transplanted tumors, whereas treatment with DFO increased survival and decreased the tumor size (Fig. 8, a and b) . Using this model, we did not observe a sig nificant reduction in tumor growth for mice treated with VD alone (Fig. 8 c) . However, the combination of VD with DFO significantly reduced tumor growth (Fig. 8 d) . The parameters of serum iron homeostasis, such as serum transferrin and ferritin levels, were significantly modified in the treated mice, which is an indication of effective iron deprivation (Fig. 8 e) . The reduced tumor growth was associated with tumor cell apoptosis, which are features of cellular differentiation and MAPK phosphorylation (ERK and JNK; Fig. 8 f) . In mice xenografted with OCIAML3 cells, DFO greatly improved eventfree survival (Fig. S8 a) . There was no significant dif ference in eventfree survival between mice treated with DFO and DFO + VD. However, a significant reduction in tumor growth was observed only in mice that received the DFO + VD association, although the DFOtreated mice pre sented reduction in tumor growth compared with control which did not reach significance (Fig. S8 b) .
Case report
Because both iron chelators and VD analogues are safe drugs currently used as therapies in the treatment of diseases other than leukemia, their effectiveness in one AML patient was evaluated. A 69yrold man had a recent transformation of MDS into AML. After highdose chemotherapy, the patient remained in nonblastic aplasia. 7 mo after the diagnosis, blasts reappeared in the blood. Highdose chemotherapy was denied, and treatment with an iron chelator (1 g/d DFX) and 25 hydroxycholecalciferol (4,000 IU/d) was initiated.
Blast counts, although progressing before therapy, were decreased upon iron chelation and vitamin D therapy, and pancytopenia was partially reversed, accompanied by an increase in monocyte numbers (Fig. 9 a) without inducing hypercalcemia (Fig. 9 b) . Importantly, May Grünwald Giemsa (MGG) blood smears revealed an increased number of differ entiating cells toward the monocyte lineage, suggesting that they were derived from the blast pool (Fig. 9 c) . Cell sorting (Fig. 9 d) , followed by fluorescent in situ hybridization analy sis, showed that the original trisomy 8 found in the blasts of the patient (Fig. 9 e) was segregated with the sorted mature monocyte population but not with lymphocytes or NK cells (Fig. 9 f) , confirming that the circulating monocytes were derived from the blast pool. In addition, the patient's quality of life was improved because red cell and platelet transfusion needs were decreased. Furthermore, the patient could con trol several microbial infections that otherwise would have been life threatening, suggesting that the patient's immune status was partially restored. These data underscore the differ entiating efficiency of combined therapy in human AML.
DISCUSSION
We show in this paper that iron homeostasis plays a key role in the control of myeloid differentiation in both normal and pathological situations. Iron deprivation of undifferenti ated myeloid cells, either through iron chelation or through blocking of iron uptake, induced transcription of several markers of the monocyte/macrophage lineage. At the same time, iron deprivation shunted progenitors away from the gran ulocytic lineage by dampening the transcription of granulocyte specific markers. Morphological, phenotypic, and functional analyses confirmed and extended these observations. Not only did iron deprivation induce primary progenitor commitment toward the monocyte lineage, it also reestablished differentia tion in AML blasts/cell lines.
Recent cumulated data in the literature have shown that ROS can modulate the activation of signal transduction path ways involved in several cellular functions such as cell prolif eration and differentiation (Sattler et al., 1999) . Specifically, in the mammalian hematopoietic system, it has been recently reported that hematopoietic stem cells produce low levels of ROS, which are increased in common myeloid progenitors. Modulation in ROS levels seems to be important in the control of myeloid precursor differentiation (Tothova et al., 2007) . (f) Serum-starved HL60 cells were incubated with 10 µg/ml A24 or 3 µM DFO and treated with 250 nM VD or mock treated for 30 min at 37°C. Whole cell extracts from the treated cells were analyzed by immunoblotting, demonstrating the increased phosphorylation of JNK when VD is combined with A24 or DFO. HSC70 and total ERK were used as loading controls. One representative experiment of three is shown. (g) Fold increase of CD14 and CD11b expression analyzed by flow cytometry (MFI relative to untreated cells) in primary blasts from two AML patients, identified as SL4 (AML2 FAB subtype) and SL12 (AML0 FAB subtype). Cells were treated with 10 µg/ml A24, 5 µM DFO, 3 µM DFX, or 250 nM VD or their association as indicated for 72 h (mean ± SEM, n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
This process seems to be conserved throughout evolution be cause Drosophila melanogaster multipotent hematopoietic progenitors display increased levels of ROS which are down regulated during differentiation (OwusuAnsah and Banerjee, 2009 ). However, factors controlling ROS production in myeloid progenitors are not well known. We show in this paper that intracellular LIP could be one of these factors playing a critical role in controlling ROS levels and, thus, cell differentiation in the hematopoietic system. Scavenging ROS from Drosophila melanogaster hemato poietic progenitors delays mature blood cell differentiation, which is dependent on the MAPK JNK (OwusuAnsah and Banerjee, 2009) . In this paper, we show that both genetic and pharmacological inactivation of the MAPK-JNK path way inhibited iron deprivationinduced cell differentia tion. Furthermore, pharmacological blocking of ROS abrogated iron deprivation-induced cell differentiation, suggesting that ROS and MAPK pathways are linked, most probably by the direct effect of ROS on MAPK activation (Martindale and Holbrook, 2002) . Signal transduction cascades of MAPK pathways frequently converge to amplify signaling (Johnson and Lapadat, 2002; LopezBergami et al., 2007) . Inhibition of ERK and p38 pathways prevented cell differentiation in duced by iron deprivation. Blocking of the ERK pathway did not block apoptosis induced by iron chelators, suggesting that redundant and nonredundant MAPK signaling pathways are involved in the control of AML cell differentiation and apoptosis. In agreement, it has been previously shown that the MAPK-ERK pathway is constitutively active in AML cells and in GCSF-mobilized CD34 + precursors and inhibi tion of ERK pathway promotes growth arrest rather than apoptosis (Ricciardi et al., 2005) . Combining iron chela tion therapy with other MAPK/ERK activators, such as GCSF, remains to be evaluated. Altogether those data suggest that cross talk between MAPK pathways could co operate to regulate AML cell differentiation and its sensitivity to cytotoxic agents.
In the majority of the experiments presented in this paper, TfR1 targeting by A24 mimicked the effect of iron chelators at least in in vitro and ex vivo settings. Because each of the ironchelating agents has its own chemical/biochemi cal characteristics (such as the structure or cellpermeant properties of the different iron chelators and cell targeting specificity of the monoclonal antibody) and pharmacological properties (such as the kinetics and halflife), the intensity of the response varied among them. For example, in tumor xenograft experiments, A24 mAb totally inhibited tumor en graftment, whereas iron chelators delayed the tumor growth, a difference probably involving additional effects of A24 such as antibodydependent cellular cytotoxicity or complement dependent cytotoxicity. In addition, A24 could exert a spe cific target effect by inducing TfR1 downregulation specifically on TfR high tumor cells (Moura et al., 2004; Lepelletier et al., 2007; Callens et al., 2008) , whereas iron chelators are more likely to induce TfR1 messenger RNA (mRNA) stability by posttranscriptional mechanisms.
The principal molecular mechanism drawn from the ex periments reported in this paper links the signaling pathways activated by iron deprivation and by VD. Gene expression studies showed a high similarity (30% common genes) be tween genes modulated by VD and the set of 105 genes targeted by iron deprivation. In addition, iron deprivation induced both VDR gene expression and VDR phosphoryla tion. The phosphorylation of VDR on serine 208 by casein kinase II has been shown to control activation of VDR gene transcription and VDR target genes expression (Jurutka et al., 1996) . Therefore, iron deprivation could induce, by itself, the activation of VDR signaling pathway. Furthermore, the com bination of iron deprivation agents and differentiating thera pies acted synergistically, increasing AML cell differentiation.
Altogether, our data identified a mechanism involving se quentially irondeprivation, ROS production, and activation of MAPK pathways, further amplified by induction of VDR expression and phosphorylation, culminating in monocyte/ macrophage differentiation. Recent studies showed an un expected constitutive activation of Syk tyrosine kinase in AML blasts (Hahn et al., 2009) . Gefitinib has been identified as a Syk tyrosine kinase inhibitor (Hahn et al., 2009 ) and reported to be a potent inducer of AML cell differentiation in preclini cal settings (Boehrer et al., 2008) . These studies unveiled Syk as a previously unsuspected regulator of AML differentiation. Although the molecular pathways regulating the activation of Syk in AML cells remain unknown, a study by Agramonte Hevia et al. (2003) reported that VDinduced cell differentia tion downregulated the high Syk activation observed in undifferentiated THP1 cells. Therefore, downmodulation The horizontal bars represent the mean of each group (n = 14 in the control group, n = 14 in the DFO group, and n = 12 in the DFO + VD group). (e) Serum ferritin and transferrin levels in xenografted mice. 25 d after the engraftment, the mice were euthanized, and serum was collected for biochemical analysis (mean ± SEM). (f) Sections of tumors from mice injected with vehicle, DFO, and DFO + VD were stained by HE, TUNEL, or labeled with CD11b-, p-ERK-or p-JNK-specific antibodies. The arrows indicate apoptosis. Representative photos of one experiment are shown. Data were quantified using Image J software. Bar, 50 µm. Histograms represent quantification of at least four different fields. One representative experiment is shown (mean ± SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
of Syk activity downstream VDR activation could participate in cell differentiation induced by iron deprivation agents and it remains to be evaluated.
VD is known to induce myeloid progenitors to differen tiate into monocytes. In vitro and ex vivo experiments were promising, but in the first clinical trials in AML and MDS, only partial differentiation was obtained and clinical improve ments were modest (Deeb et al., 2007) . In addition, symp tomatic hypercalcemia limited VD clinical application. Clinical trials using VD analogues, which do not promote hypercal cemia, did not improve patients' prognosis (Koeffler et al., 2005) , suggesting that VDR stimulation alone is not suffi cient to promote clinical benefit. We show in this paper that iron deprivation could be a new therapeutic approach in AML, and likely in MDS, because it synergizes with VD (low dose). The combination of iron chelators and VD induced both prodifferentiating and antiproliferative effects in leuke mia cells from one AML patient, as described in this paper in the form of a case report. This association reduced the rate of blast proliferation and promoted blast differentiation toward monocytes without emergence of hypercalcemia. The pa tient developed multiple infectious episodes, which were greatly reduced after the initiation of VD and iron chelation combined therapy. In vitro experiments showed that, in ad dition to its role in monocyte differentiation, the associated therapy promoted expression of genes related to antimicro bial defense such as cathelicidin. Therefore, the early use of iron chelators in AML therapy, in addition to preventing re lapses and enhancing time to progression, could act at multi ple levels: by preventing red cell transfusionderived secondary iron overload, by avoiding defective bone marrow reconsti tution after allogeneic HSCT, and also by improving patients' immune status (Pullarkat et al., 2008; Pullarkat, 2009) .
Because AML incidence increases with age and because the world population is growing older, we propose that the combined therapy would be particularly useful in elderly pa tients who are not eligible for high dose chemotherapy and bone marrow transplantation. This combined therapy could be also relevant in other diseases involving a deregulation of BM differentiation, such as MDS. Additional clinical studies are needed to validate its efficacy and determine in which patients it will be more beneficial.
MATERIALS AND METHODS
Clinical samples and cell lines. Peripheral blood cells were obtained from AML patients and healthy donors after obtaining their written informed consent (Table S2 , additional information) and approval obtained by the Necker and SaintLouis Hospitals Institutional ethic committees. Peripheral blood was collected at the initial diagnosis before the administration of treat ment. Mononuclear cells were separated by Ficollhypaque (PAA laboratories) density centrifugation and resuspended in IMDM (Invitrogen) supple mented with 15% FCS (Hyclone), 100 ng/ml stem cell factor (SCF), 10 ng/ml IL3, and 25 ng/ml FLT3L (all purchased from R&D Systems). Myelocytic (HL60 and OCIAML3), monoblastic (THP1 and U937), and promyelo cytic (NB4) leukemia cell lines used in the present study were provided by J.M. Cayuela (Hôpital SaintLouis, Paris, France) and P. Villarese (Hôpital Necker, Paris, France). Cells were cultured in RPMI1640 medium (In vitrogen) supplemented with 5% FCS and antibiotics.
Cell treatment and proliferation assays. DFX was provided by Novartis. Etoposide (VP16), ATRA, DFO, 25OHVD, H 2 O 2 , FeCl 3, NAC, and PDTC were purchased from SigmaAldrich. CalceinAM, DHR123, and DHE were purchased from Invitrogen. The mAb A24 was produced and purified as described previously (Moura et al., 2001) . The inhibitors of JNK (SP600125), ERK (PD98059), and p38 (SB203580) were obtained from Santa Cruz Biotechnology, Inc.
For proliferation assays, the HL60 cell line was resuspended in RPMI 1640 medium with 5% FCS, whereas the patient blasts were resuspended in IMDM with 15% BIT 9500 (STEMCELL Technologies Inc.). The cells were plated in triplicate at 2.5 × 10 4 cells per well in 96well tissue culture plates (Falcon) in 200 µl of culture medium. Proliferation was measured as described previously (Lepelletier et al., 2007) .
Calcein assay for intracellular LIP. LIP was evaluated according to a previously described method (Espósito et al., 2002) with some modifica tions. In brief, cells were treated with 0.5 µM calceinAM for 30 min at 37°C. Before being subjected to flow cytometry analysis, cells were treated or not with an excess of cellpermeant iron chelators. The fluorescein chan nel was used to detect calcein fluorescence. The difference between calcein fluorescence before and after adding cellpermeant iron chelators indicated the relative amount of LIP (Espósito et al., 2002) .
Measurement of intracellular ROS.
Fluorescence analysis was used to determine the relative levels of ROS in response to various stimuli. ROS levels were detected by FACS analysis. Labeling with cellpermeant redox sensitive fluorochromes was performed for 30 min at 37°C in the presence of 1 µM DHE or 0.5 µM DHR123, both diluted in 0.5% BSA in HBSS solution (Invitrogen).
Overexpression and silencing of JNK1, JNK2, and c-Jun. For overex pression, pEGFPC3 (Takara Bio Inc.) expression vectors containing cDNA encoding JNK1 or JNK2 between the HindIII/BamHI sites (pro vided by T. Herdegen, Institute of Pharmacology, University Hospital SchleswigHolstein, Kiel, Germany) were used. These proteins were ex pressed as a GFP fusion protein under the control of human CMV im mediate early promoter.
For C-Jun, JNK1, and JNK2 gene silencing, artificial miRNA constructs were generated. Four sets of predesigned miR RNAi sequence oligonucle otides for each gene were obtained using BLOCKiT miR RNAi Select (Invitrogen) and checked to ensure the designed sequences would not target other gene transcripts to avoid any offtarget effects. These oligonucleotides were annealed and ligated into the pcDNA6.2GW/EmGFPmiR vector according to the manufacturer's instructions (Invitrogen) to express the premiRNA as an EmGFP fusion under the control of human CMV imme diate early promoter. The pcDNA 6.2GW/EmGFPmiR-negative control plasmid contains a scrambled miRNA insert, which is predicted not to target any known vertebrate gene.
HL60 cells were transfected with the plasmids using a nucleofector (Lonza) as described according to the manufacturer's instructions (usually 40% cells were transfected). 5 µM DFO was added in culture medium 48 h after transfection and flow cytometry analysis was realized 24 h later on the At diagnosis, undifferentiated blasts were predominantly observed in MGG-stained blood cytosmears. 1 mo after beginning treatment, the blasts started to present signs of monocyte differentiation, such as nuclear deformation, cytoplasm enlargement, and the presence of vacuoles. After 3 mo of treatment, undifferentiated blasts were replaced by monocytoid blasts and pro-monocytes. After 4 mo, some monoblasts were still detected, but mature monocytes were predominantly observed. Representative photos of each blood cytosmears are shown. Cytogenetic analysis. FISH was performed using standard protocols with specific centromeric probes for chromosome 8 (pZ8.4) and chromosome 12 (pBR12; provided by M. Rocchi, University of Bari, Bari, Italy) used as control.
RNA isolation, real-time quantitative PCR, and transcriptome analysis. Total RNA from timematched controls and treated samples was extracted using NucleoSpin RNA II (MachereyNagel). After DNase treat ment, firststrand cDNA was synthesized using SuperScript II reverse tran scription (Invitrogen). Quantitative realtime PCR was performed using a ChromoIV PCR System (MJ Research), and the PCR products were quantified using Sybr Green Technology (Jumpstart MasterMix; Sigma Aldrich). The results of the realtime quantitative PCR were analyzed using the deltadelta Ct method (Livak and Schmittgen, 2001 ). The complete list of primer sequences is available in Table S4 .
For the microarrays, the Agilent 44 K Whole Human Genome (G4112A) long (60 bp) oligonucleotide microarray and the dualcolor analy sis method were used with probes from the treated samples and from refer ence RNA that were differentially labeled with cyanine 5 and cyanine 3. These microarrays have 44,290 features with 41,000 distinct oligonucle otides belonging to 33,715 sequences defined by their accession number. cRNA from each treated sample was labeled with Cy3cytidine triphosphate (CTP) and the untreated HL60 RNA reference pool with Cy5CTP for direct comparison. Reverse transcription, linear amplification, cRNA label ing, and cRNA purification were performed with the linear amplification kit (Agilent Technologies). The microarray data were mainly analyzed with the Resolver software (Merck). All data were filtered to eliminate lowintensity values <50 arbitrary units for both colors. The microarray data analyzed in this paper have been submitted to the Array Express data repository at the European Bioinformatics Institute (http://www.ebi.ac.uk/arrayexpress/) under accession no. ETABM925.
Tumor xenografts. For tumor establishment, 5 × 10 6 HL60 or 2.5 × 10 6 OCIAML3 cells were mixed with Matrigel (1:1, vol/vol) and injected sub cutaneously into 8-10wkold female athymic Nude mice. The mice were then injected i.p. with A24 (40 mg/kg on day 1), DFO (20 mg/day, 5-7×/wk), VD (1 µg, 2×/wk), and the combination of DFO and VD or PBS as a vehicle control. The tumor growth was measured as previously described (Lepelletier et al., 2007) .
Immunohistochemistry. Serial sections (3 µm) in paraffin blocks were deparaffinized in xylene and hydrated in a graded series of alcohol. Staining was performed using the Immunohistochemical Autostainer (Laboratory Vision Corporation) with primary antibodies against CD11b (Sigma Aldrich, 1:200), pERK, and pJNK (Cell Signaling Technology, 1:200), biotinylated antiIg, and streptavidinperoxidase. The antibody binding was developed in PBS with 0.05% DAB and 0.003% H 2 O 2 . Hematoxylineosin (HE)-stained sections were used to evaluate cytomorphology and to detect apoptotic cells with condensed nuclei. Apoptosis was assessed by the TUNEL technique according to the manufacturer's instructions (Roche). The images were obtained using a microscope (DM2000; Leica) equipped with a digi tal camera (DFC320; Leica) and IM50 software. Data were quantified us ing Image J software (National Institutes of Health).
Cord blood cell cultures and methylcellulose colony-forming assays. CD34 + cord blood cells were isolated by immunomagnetic separa tion (Miltenyi Biotec) and cultured in IMDM supplemented with 15% BIT 9500 (Stem Cell Technologies), 100 ng/ml SCF, 10 ng/ml IL3, 25 ng/ml GCSF, and 10 ng/ml GMCSF for myelomonocytic differenti ation (all cytokines were purchased from R&D Systems). 10 µg/ml A24, 5 µM DFO, or 3 µM DFX was added iteratively every 3 d in the culture medium.
For colonyforming assays, 10 3 CD34 + cells were plated in quadrupli cate in semisolid methylcellulose medium (H4434; Stem Cell Technologies) in the presence or absence of 10 µg/ml A24, 5 µM DFO, or 3 µM DFX. At day 14, colonies containing >50 cells were counted and classified as gran ulocyte colony (CFUG), monocytemacrophage colony (CFUM), mixed granulocytemonocyte colony (CFUGM), or erythroid colony (CFUE). The colonies were counted by standard criteria in 60mm gridded scoring dishes with cross marks (Stem Cell Technologies) under an inverted micro scope. To verify if iron deprivation leads to an altered formation of myelo monocytic colonies, we represented the ratio between CFUG and CFUM in both nontreated and treated groups.
Analysis of cellular differentiation and apoptosis. Cell differentiation was determined by the following criteria: cell morphology was evaluated after MGG staining. Esterase activity was detected using the LEUCOGNOST EST kit (Merck). The expression of CD11b (IM2581U; Beckman Coulter) and CD14 (A07765; Beckman Coulter) was evaluated by flow cytometry (FACSCalibur; BD). Cell death was evaluated using the annexinV/ propidium iodide (PI) double staining kit (BD) according to the manu facturer's instructions.
Immunoblotting. All experiments were made with serumstarved cells (12-16 h) to avoid detection of constitutive phosphorylation induced by growth factors (Wang and Proud, 2007) . Whole cell extracts were prepared as described previously (AmirMoazami et al., 2008) . In brief, cell pellets (10 7 cells) were washed twice with PBS and then resuspended in 1 ml of lysis buffer (20 mM TrisHCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X100, 2.5 mM sodium pyrophosphate, 1 mM hglycero phosphate, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, and 1 µg/ml aprotinin). The protein concentration was deter mined using the BCA method (Thermo Fisher Scientific) and an equal amount of SDS sample buffer containing 150 mM TrisHCl, pH 6.8, 30% glycerol, 3% SDS, 1.5 mg/ml bromophenol blue, and 100 mM DTT was then added to each sample. For immunoblotting, 40 µg of protein was sepa rated in 4-12% or 7% SDSPAGE and transferred onto a PVDF membrane. The blots were first probed with an antiphospho protein, pERK (Thr202/ Tyr204), pJNK, pp38 (all from Cell Signaling Technology), or pVDR (Ab63572; Abcam) antibody. The membranes were stripped, dried, and probed with an antibody against total ERK (Cell Signaling Technology), VDR (Ab39990; Abcam), or HSC70 (sc71270; Sants Cruz Biotechnology, Inc.). The protein bands were visualized using a chemiluminescence system.
